Single-dose genetic medicine halts the progression of ALS and frontotemporal dementia in mice

Neuroscientists at Macquarie University in Australia have developed a single-dose genetic medicine that has been proven to halt the progression of both ALS and frontotemporal dementia (FTD) in mice – and may even offer the potential to reverse some of the effects of the fatal diseases.

VCs move to launch U.S.-based companies to develop drugs developed in China

As Chinese biopharma companies rise on the international stage, they are increasingly finding VC partners — in the United States. U.S. companies have long signed

October 29, 2024

ACS Guidelines Expand Lung Cancer Screening Eligibility — Is That a Good Thing?

BOSTON — Whether low-dose CT screening for lung cancer should be expanded to include people who quit smoking more than 15 years ago, as the

October 12, 2024

New treatment breakthrough: Pyrotinib combo demonstrates remarkable efficacy for HER2 positive metastatic breast cancer

The safety and efficacy of treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with pyrotinib.

November 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.